Start Date: 1/11/2001 8:00 AM
End Date: 1/11/2001 4:00 PM
An Industry Liaison Group was formed in order to promote a dialogue between the recently formed Pharmacogenetics Research Network and Knowledge Base (PharmGKB) and members of the pharmaceutical industry. The January 11 meeting was a forum to identify common areas of interest and complementary goals, to pursue at the present time and in the future. A joint roster and agenda are below.
Members of the Industry Liaison Group indicated that the pharmaceutical industry will likely have an interest in using PharmGKB. They recommended working with the Pharmacogenetics Research Network on several common areas of high priority for both industry and academia. These areas are: 1) educating the public about the potential value of pharmacogenetics research, 2) sharing expertise in pre-competitive areas (e.g., nomenclature, analytic tools, ethics), and 3) continuing individual research collaborations in areas of mutual scientific interest. Specific topics discussed and identified for follow-up include sharing common standards for terminology used in protocol designs, exchanging language used in informed consents, and emphasizing the protection of patient confidentiality. The group recommended further coordination and exchange of non-proprietary information.
Russ B. Altman, M.D., Ph.D. Stanford University Medical School Office Building, X-215 251 Campus Drive Stanford, CA 94305-5479
Donald C. Anderson, M.D. Pharmacia Corporation 7000 Portage Road 7272-24-113 Kalamazoo, MI 49001-0199
Christopher P. Austin, M.D. (not in attendance) Merck Research Laboratories WP26A-3000 P.O. Box 4 West Point, PA 19486
Lee E. Babiss, Ph.D. Hoffmann-La Roche Inc. Preclinical Research and Development 340 Kingsland Street Nutley, NJ 07110
Kathleen M. Giacomini, Ph.D. University of California, San Francisco School of Pharmacy, Box 0446 513 Parnassus Avenue San Francisco, CA 94143-0446
Penelope K. Manasco, M.D. GlaxoSmithKline 5 Moore Drive Building 5, Room 5804 Research Triangle Park, NC 27709
Mark J. Ratain, M.D. University of Chicago 5841 South Maryland Avenue, MC 2115 Chicago, IL 60637-1470
Brian B. Spear, Ph.D. Abbott Laboratories Department 424, AP6A-1 100 Abbott Park Road Abbott Park, IL 60064-6008
Vincent P. Stanton, Jr., M.D. Variagenics, Inc. 60 Hampshire Street Cambridge, MA 02139
Richard M. Weinshilboum, M.D. Mayo Foundation Rochester Division of Pharmacology 200 First Street, S.W. Rochester, MN 55905
Scott Weiss, M.D. Channing Laboratories Brigham and Women's Hospital 75 Francis Street Boston, MA 02115
NIGMS Program Director
Rochelle M. Long, Ph.D. Division of Pharmacology, Physiology, and Biological Chemistry National Institute of General Medical Sciences National Institutes of Health Natcher Building, Room 2AS.49G 45 Center Drive MSC 6200 Bethesda, MD 20892-6200 Tel: (301) 594-1826 Fax: (301) 480-2802 rochelle_long@nih.gov Assistant: Michelle Blanco Tel: (301) 594-1826 michelle_blanco@nih.gov
NIGMS Observers
Richard A. Anderson, M.D., Ph.D. Division of Genetics and Developmental Biology National Institute of General Medical Sciences National Institutes of Health Natcher Building, Room 2AS.25B 45 Center Drive MSC 6200 Bethesda, MD 20892-6200 Tel: (301) 594-0943 Fax: (301) 480-2228 andersor@nigms.nih.gov
Marvin Cassman, Ph.D. Director National Institute of General Medical Sciences National Institute of Health Natcher Building, Room 2AN.12B 45 Center Drive MSC 6200 Bethesda, MD 20892-6200 Tel: (301) 594-2172 Fax: (301) 402-0156 cassmanm@nigms.nih.gov
Michael Rogers, Ph.D. Director Division of Pharmacology, Physiology, and Biological Chemistry National Institute of General Medical Sciences National Institutes of Health Natcher Building, Room 2AS.49G 45 Center Drive MSC 6200 Bethesda, MD 20892-6200 Tel: (301) 594-1829 Fax: (301) 480-2802 michael_rogers@nih.gov
8:30 a.m. — Continental Breakfast
9:00 a.m. — Welcome on Behalf of NIGMS, NIH Marvin Cassman
9:10 a.m. — Charge to the Group ( Questions List ) Mark Ratain
9:20 a.m. — Overview/Background of the Pharmacogenetics Research Network Rochelle Long
Discussion of the Initiative
10:00 a.m. — Presentation of the PharmGKB Russ Altman
Discussion of the Knowledge Base
10:50 a.m. — Break
11:00 a.m. — Research Summaries Kathy Giacomini Dick Weinshilboum Scott Weiss Mark Ratain
12:00 p.m. — Lunch
1:00 p.m. — Industry Presentations Brian Spear Penny Manasco Lee Babiss Vince Stanton Donald Anderson
2:15 p.m. — General Discussion Review of the Questions List
Discussion of the Industry/Academic Panel at April 25, 2001 Meeting
4:00 p.m. — Adjourn
PharmGKB, the Pharmacogenetics Knowledge Base
Academic/Industry Interactions
Approaches to Pharmacogenetics Studies
